Skip to content
How It Works
Explore
Resources Ask a Question
Who It's For
Patients Caregivers Providers
Log In Ask a Question
PubMed This is a summary of 15 peer-reviewed journal articles Updated
Neurology

Building Your Care Team and Managing the Condition

At a Glance

Managing genetic neuropathy requires a proactive, multidisciplinary care team. Treatment focuses on targeted physical therapy, custom orthotics like AFOs to prevent falls, and pain management. Some specific subtypes, like hATTR, now have FDA-approved medications that can slow disease progression.

While most genetic neuropathies do not yet have a “cure,” the way you manage the condition can significantly impact your mobility, comfort, and independence. Management is moving away from just “watching and waiting” toward a proactive, multidisciplinary approach that targets symptoms and, in some cases, the underlying disease process [1][2].

Your Multidisciplinary Care Team

Because genetic neuropathy affects how you move, feel, and function, you need a team of specialists who look at the problem from different angles:

  • Neurologist: The “quarterback” of your team who confirms your diagnosis, monitors nerve health, and stays up-to-date on new treatments [1].
  • Physiatrist: A doctor of physical medicine and rehabilitation who focuses on your overall function and coordinates your therapy needs [3].
  • Physical Therapist (PT): Focuses on improving your balance, walking stability, and muscle strength [3][4].
  • Orthotist: A specialist who designs and fits AFOs (Ankle-Foot Orthoses) or other braces to help with foot drop and prevent falls [5][6].
  • Genetic Counselor: Helps you understand your test results and what they mean for your family members or future children [1].

Standard of Care: Managing Symptoms

For the majority of genetic neuropathies, including most types of CMT, treatment is focused on supportive care:

  • Physical and Occupational Therapy: These are the foundations of care. The goal is to maintain your current range of motion and functional independence. A PT experienced in neuropathy will ensure you don’t over-fatigue your muscles. With genetic neuropathy, the rule is not to “push through the burn.” Overworking weakened muscles can cause further damage; exercise should focus on gentle strengthening and maintaining flexibility without leaving you exhausted [3][4][7].
  • Orthotics and Bracing: AFOs are often life-changing for patients with foot drop, as they “clear” the foot during a step and significantly reduce the risk of tripping. If the idea of a brace sounds scary or bulky, know that modern AFOs are often made of lightweight carbon fiber and can fit easily underneath pants and inside normal shoes [5][3].
  • Pain Management: Genetic neuropathy can cause both nerve pain (burning, tingling) and musculoskeletal pain (from walking differently). Management may include medications, specialized massage, or stretching routines [7].

Emerging and Specialized Treatments

The landscape of treatment is changing rapidly, especially for certain subtypes:

hATTR (Amyloidosis) Treatments

Unlike other genetic neuropathies, hATTR has several FDA-approved disease-modifying therapies that can slow or even stop the progression of nerve damage [8]:

  • TTR Stabilizers (e.g., Tafamidis): These medications act like “glue” to keep the transthyretin protein from breaking apart and forming toxic clumps [9].
  • TTR Silencers (e.g., Patisiran, Vutrisiran, Inotersen): These advanced therapies use “gene-silencing” technology to stop the liver from making the faulty protein in the first place [10][11].

CMT Clinical Trials

While there are no FDA-approved drugs specifically for CMT yet, research is active. One of the most advanced candidates is PXT3003, a combination of three existing medications (baclofen, naltrexone, and sorbitol). Phase 3 clinical trials (such as the PREMIER trial) have shown it may help improve disability scores in patients with CMT1A [12][13]. Other research is looking into using CRISPR or other gene-editing tools to fix the genetic mutations at their source [14][15].

Common questions in this guide

Who should be on my care team for genetic neuropathy?
Your care team should typically include a neurologist to monitor nerve health, a physiatrist or physical therapist to improve mobility, an orthotist to fit helpful braces, and a genetic counselor to explain your test results.
How should physical therapy be different for genetic neuropathy?
Physical therapy for genetic neuropathy should focus on gentle strengthening and maintaining balance without causing exhaustion. Because weakened muscles can be easily damaged, you should avoid pushing through the burn or overworking your muscles.
What are AFOs and how do they help with foot drop?
AFOs, or Ankle-Foot Orthoses, are specialized lightweight braces that support the foot and ankle. They help clear your foot off the ground when you step, which significantly reduces the risk of tripping and falling due to foot drop.
Are there any disease-modifying treatments for genetic neuropathy?
While most genetic neuropathies rely on symptom management, the hATTR subtype has FDA-approved treatments called TTR stabilizers and silencers. These advanced medications can slow or even stop the progression of nerve damage by targeting the specific faulty proteins.
Are there new treatments being researched for CMT?
Yes, there are active clinical trials for Charcot-Marie-Tooth disease, including investigations into combination medications like PXT3003. Researchers are also exploring gene-editing technologies like CRISPR to potentially fix the underlying genetic mutations.

Questions to Ask Your Doctor

Curated prompts to bring to your next appointment.

  1. 1.How many patients with my specific subtype of genetic neuropathy do you currently manage?
  2. 2.Can you refer me to a physiatrist or physical therapist who has experience with muscle-wasting conditions like CMT?
  3. 3.Am I a candidate for any current clinical trials, like those investigating PXT3003 or gene-silencing therapies?
  4. 4.What is the plan for monitoring my disease progression—how often should we repeat nerve conduction studies or strength tests?
  5. 5.For hATTR, which specific disease-modifying therapy (stabilizer vs. silencer) do you recommend for my stage of polyneuropathy?

Questions For You

Tap a prompt to share your answer — we'll use it plus this page's context to start a tailored conversation.

References

References (15)
  1. 1

    Understanding medication safety and Charcot-Marie-Tooth disease: a patient perspective.

    Socha Hernandez AV, Deeks LS, Shield AJ

    International journal of clinical pharmacy 2020; (42(6)):1507-1514 doi:10.1007/s11096-020-01123-z.

    PMID: 32804316
  2. 2

    Quality of life outcomes in APOLLO, the phase 3 trial of the RNAi therapeutic patisiran in patients with hereditary transthyretin-mediated amyloidosis.

    Obici L, Berk JL, González-Duarte A, et al.

    Amyloid : the international journal of experimental and clinical investigation : the official journal of the International Society of Amyloidosis 2020; (27(3)):153-162 doi:10.1080/13506129.2020.1730790.

    PMID: 32131641
  3. 3

    The Role of Rehabilitation in the Management of Patients with Charcot-Marie-Tooth Disease: Report of Two Cases.

    Dimitrova EN, Božinovikj I, Ristovska S, et al.

    Open access Macedonian journal of medical sciences 2016; (4(3)):443-448 doi:10.3889/oamjms.2016.079.

    PMID: 27703571
  4. 4

    Impact of Customized and Sustained Physiotherapy in Charcot-Marie-Tooth Disease.

    Chitapure T, Jethwani D, Zubair Ahmed S, Panigrahy C

    Cureus 2021; (13(8)):e17201 doi:10.7759/cureus.17201.

    PMID: 34540429
  5. 5

    Frequency and circumstances of falls for people with Charcot-Marie-Tooth disease: A cross sectional survey.

    Ramdharry GM, Reilly-O'Donnell L, Grant R, Reilly MM

    Physiotherapy research international : the journal for researchers and clinicians in physical therapy 2018; (23(2)):e1702 doi:10.1002/pri.1702.

    PMID: 29282812
  6. 6

    Correlates of functional ankle instability in children and adolescents with Charcot-Marie-Tooth disease.

    Rose KJ, Hiller CE, Mandarakas M, et al.

    Journal of foot and ankle research 2015; (8()):61 doi:10.1186/s13047-015-0118-1.

    PMID: 26543504
  7. 7

    Massage therapy treatment and outcomes in a patient with Charcot-Marie-Tooth disease: A case report.

    Paz G

    Journal of bodywork and movement therapies 2020; (24(2)):130-137 doi:10.1016/j.jbmt.2019.10.014.

    PMID: 32507138
  8. 8

    An indirect treatment comparison of the efficacy of patisiran and tafamidis for the treatment of hereditary transthyretin-mediated amyloidosis with polyneuropathy.

    Planté-Bordeneuve V, Lin H, Gollob J, et al.

    Expert opinion on pharmacotherapy 2019; (20(4)):473-481 doi:10.1080/14656566.2018.1554648.

    PMID: 30489166
  9. 9

    Diagnosis and Treatment of Hereditary Transthyretin Amyloidosis (hATTR) Polyneuropathy: Current Perspectives on Improving Patient Care.

    Luigetti M, Romano A, Di Paolantonio A, et al.

    Therapeutics and clinical risk management 2020; (16()):109-123 doi:10.2147/TCRM.S219979.

    PMID: 32110029
  10. 10

    Hereditary transthyretin amyloidosis: a model of medical progress for a fatal disease.

    Adams D, Koike H, Slama M, Coelho T

    Nature reviews. Neurology 2019; (15(7)):387-404 doi:10.1038/s41582-019-0210-4.

    PMID: 31209302
  11. 11

    Characteristics of Patients with Hereditary Transthyretin Amyloidosis-Polyneuropathy (ATTRv-PN) in NEURO-TTRansform, an Open-label Phase 3 Study of Eplontersen.

    Coelho T, Waddington Cruz M, Chao CC, et al.

    Neurology and therapy 2023; (12(1)):267-287 doi:10.1007/s40120-022-00414-z.

    PMID: 36525140
  12. 12

    A double-blind, placebo-controlled, randomized trial of PXT3003 for the treatment of Charcot-Marie-Tooth type 1A.

    Attarian S, Young P, Brannagan TH, et al.

    Orphanet journal of rare diseases 2021; (16(1)):433 doi:10.1186/s13023-021-02040-8.

    PMID: 34656144
  13. 13

    Early short-term PXT3003 combinational therapy delays disease onset in a transgenic rat model of Charcot-Marie-Tooth disease 1A (CMT1A).

    Prukop T, Stenzel J, Wernick S, et al.

    PloS one 2019; (14(1)):e0209752 doi:10.1371/journal.pone.0209752.

    PMID: 30650121
  14. 14

    Gene therapy and other novel treatment approaches for Charcot-Marie-Tooth disease.

    Pisciotta C, Pareyson D

    Neuromuscular disorders : NMD 2023; (33(8)):627-635 doi:10.1016/j.nmd.2023.07.001.

    PMID: 37455204
  15. 15

    Challenges in Treating Charcot-Marie-Tooth Disease and Related Neuropathies: Current Management and Future Perspectives.

    Pisciotta C, Saveri P, Pareyson D

    Brain sciences 2021; (11(11)) doi:10.3390/brainsci11111447.

    PMID: 34827446

This page provides general information about managing genetic neuropathies and emerging therapies. It is for educational purposes only and is not a substitute for professional medical advice from your neurologist or specialized care team.

Get notified when new evidence is published on Genetic peripheral neuropathy.

We monitor PubMed for new peer-reviewed studies on this topic and email a short summary when something meaningful changes.